Rituximab for the treatment of patients with chronic lymphocytic leukemia

Figures & data

Table 1 Phase II trials of single-agent rituximab in chronic lymphocytic leukemia patients

Authors	No of evaluable patients	Prior therapy	Rituximab dose (mg/m^2)	No of doses	Overall response rate (%)
McLaughlin et al^Citation47	30	Yes	375 q 4 weeks	4	13
Nguyen et al^Citation48	10	Yes	375 q 4 weeks	4	10
Winkler et al^Citation49	9	Yes	375 q 4 weeks	4	11
Ladetto et al^Citation50	7	Yes	375 q 4 weeks	4	0
Huhn et al^Citation9	28	Yes	375 q 4 weeks	4	25
Thomas et al^Citation52	21	No	375 q 4 weeks	8	90
Itala et al^Citation51	24	Yes	375 q 4 weeks	4	35
Hainsworth et al^Citation10	44	No	375 q 4 weeks	4	51

Table 2 Phase II rituximab-based chemoimmunotherapy regimens in chronic lymphocytic leukemia patients

Authors	No of evaluable patients	Prior therapy	Chemotherapy agents	Rituximab dose (mg/m^2)	No of cycles	Overall response rate (%)	CR rate (%)
Byrd et al^Citation13	51	No	Flu	375 q 4 weeks	6	90	47
Schulz et al^Citation18	31	No	Flu	375 q 4 weeks	4	87	32
Wierda et al^Citation16	177	Yes	Flu+Cy	500 q 4 weeks	6	73	25
Keating et al^Citation15	300	No	Flu+Cy	500 q 4 weeks	6	94	72
Kay et al^Citation26	64	No	Pent+Cy	375 q 4 weeks	6	91	41
Bosch et al^Citation23	68	No	Flu+Cy+Mito	500 q 4 weeks	6	93	82
Faderl et al^Citation24	30	No	Flu+Cy+Mito	500 q 4 weeks	6	96	83

Abbreviations: CR, complete response; Flu, fludarabine; Cy, cyclophosphamide; Pent, pentostatin; Mito, mitoxantrone.

McLaughlinPWhiteCAGrillo-LopezAJMaloneyDGClinical status and optimal use of rituximab for B-cell lymphomasOncology (Williston Park)199812176317699874849

 PubMed Web of Science ®Google Scholar

NguyenDTAmessJADoughtyHHendryLDiamondLWIDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patientsEur J Haematol199962768210052709

 PubMed Web of Science ®Google Scholar

WinklerUJensenMManzkeOSchulzHDiehlVEngertACytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)Blood1999942217222410498591

 PubMed Web of Science ®Google Scholar

LadettoMBerguiLRiccaICampanaSPileriATarellaCRituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patientsMed Oncol20001720321010962531

 PubMed Web of Science ®Google Scholar

HuhnDVon SchillingCWilhelmMRituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood2001981326133111520778

 PubMed Web of Science ®Google Scholar

ThomasDO’BrienSGilesFJSingle agent rituxan in early stage chronic lymphocytic leukemia (CLL). [abstract]Blood200198364a

 Google Scholar

ItalaMGeislerCHKimbyEStandard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre studyEur J Haematol20026912913412406005

 PubMed Web of Science ®Google Scholar

HainsworthJDLitchySBartonJHSingle-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2003211746175112721250

 PubMed Web of Science ®Google Scholar

ByrdJCPetersonBLMorrisonVLRandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood2003119976984

 Google Scholar

SchulzHKleinSKRehwaldUReiserMHinkeAKnaufWUPhase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaBlood20021003115312012384407

 PubMed Web of Science ®Google Scholar

WierdaWO’BrienSWenSChemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocyticleukemiaJ Clin Oncol2005234070407815767647

 PubMed Web of Science ®Google Scholar

KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2005234079408815767648

 PubMed Web of Science ®Google Scholar

KayNEGeyerSMCallTGCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood200710940541117008537

 PubMed Web of Science ®Google Scholar

BoschFAbrisquetaPVillamorNRituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaJ Clin Oncol2009274578458419704063

 PubMed Web of Science ®Google Scholar

FaderlSWierdaWO’BrienSFerrajoliALernerSKeatingMJFludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 yearsLeuk Res20103428428819646755

 PubMed Web of Science ®Google Scholar